Paratek Pharmaceuticals Presenting New Data from NUZYRA® (Omadacycline) and Investigator-Initiated Pre-Clinical Studies at European Society of Clinical Microbiology & Infectious Diseases Global (ESCMID Global) 2024
April 18 2024 - 6:30AM
Paratek Pharmaceuticals, Inc., a biopharmaceutical company focused
on providing innovative medical therapies that create positive
patient stories in the hospital, community and public health
settings, today announced that three new pre-clinical studies with
NUZYRA® (omadacycline) will be presented at European Society of
Clinical Microbiology & Infectious Diseases Global (ESCMID
Global, formerly ECCMID).
The hybrid conference will be held April 27-30 at the Fira Gran
Via in Barcelona, Spain. View the ESCMID scientific program.
“Paratek continues to invest in science to further our
understanding of NUZYRA, as well as explore its future utility in
addressing additional unmet patient needs,” said Randy Brenner,
chief development and regulatory officer of Paratek. “Next week’s
ESCMID presentations include a study assessing the potential
immunomodulating properties of NUZYRA in addition to its
antibacterial activity. Two additional studies expand upon our
understanding of NUZYRA for Mycobacterium abscessus and
Mycobacterium avium complex (MAC).”
NUZYRA presentation details
Presentation Title: Immunomodulatory activity of
omadacycline in vitro and in a
murine model of acute lung injury (ALI)
(Investigator-initiated research)
Time/Location: April 27, noon CEST (7:00 a.m.
U.S. EST) in poster area Abstract #:
04151Presenter: Paul Beringer, PharmD., Professor
of Clinical Pharmacy, University of Southern California Alfred E.
Mann School of Pharmacy and Pharmaceutical Sciences, Los Angeles,
CASession title: 10g – Immune response to
infection (including in vitro, animal and human studies, laboratory
assessment of immunity and response, excl sepsis biomarkers)Poster
session: P3884
Presentation Title: Omadacycline alone and in
combination as a treatment option for Mycobacterium avium
infections
Time/Location: April 28, noon CEST (7:00 a.m.
U.S. EST) in poster areaAbstract #:
00304Presenter: Saskia E. Mudde, Erasmus
University Medical Center, Department of Medical Microbiology and
Infectious Diseases, Rotterdam, NetherlandsSession
title: 2a – Tuberculosis and other mycobacterial
infections (including epidemiology, clinical, diagnostics,
antimycobacterial drugs, susceptibility testing, treatment &
prevention)Poster session: P0609
Presentation Title: Minimum inhibitory concentrations
(MICs) of tigecycline correlate strongly with those of
omadacycline
Time/Location: April 29, noon CEST (7:00 a.m.
U.S. EST) in poster areaAbstract #:
01492Presenter: Vinicius Calado Nogueira de Moura,
Division of Mycobacterial and Respiratory Infections, Department of
Medicine, National Jewish Health, Denver, COSession
title: 3c – Susceptibility testing methods (including
assay validation, phenotypic assays and comparative studies,
excluding TB)Poster session: P1563
About Paratek Pharmaceuticals, Inc. Paratek
Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical
company focused on providing innovative medical therapies that
create positive patient stories in the hospital, community and
public health settings.
The company's lead commercial product, NUZYRA® (omadacycline),
is a once-daily oral and intravenous antibiotic available in the
United States for the treatment of adults with community-acquired
bacterial pneumonia (CABP) and acute bacterial skin and skin
structure infections (ABSSSI). Paratek has a collaboration
agreement with Zai Lab Limited for the development and
commercialization of omadacycline in the greater China region and
retains all remaining global rights. Zai Lab received approval of
both IV and oral NUZYRA as a Category 1 innovative drug by the
National Medical Products Administration of China for the treatment
of CABP and ABSSSI in December 2021.Paratek is also conducting a
Phase 2b study with NUZYRA in a rare disease, non-tuberculous
mycobacterial (NTM) pulmonary disease, caused by Mycobacterium
abscessus complex.
In December 2019, BARDA awarded Paratek a contract that is now
valued at up to approximately $304 million. In addition to
supporting the development of NUZYRA for both the treatment and
prophylaxis of pulmonary anthrax, this contract supports the U.S.
onshoring of NUZYRA and manufacturing security requirements; FDA
post-marketing requirements associated with the initial NUZYRA
approval; and the procurement of up to 10,000 treatment courses of
NUZYRA for the treatment of anthrax.
For more information, visit www.ParatekPharma.com or follow us
on LinkedIn and Twitter.
About NUZYRA®NUZYRA® (omadacycline) is a novel
antibiotic with both once-daily oral and intravenous (IV)
formulations for the treatment of community-acquired bacterial
pneumonia (CABP) and acute bacterial skin and skin structure
infections (ABSSSI). A modernized tetracycline, NUZYRA is
specifically designed to overcome tetracycline resistance and
exhibits activity across a spectrum of bacteria, including
Gram-positive, Gram-negative, atypicals and other drug-resistant
strains.
MEDIA CONTACT: Christine Fanelle Scient PR
Christine@ScientPR.com215-595-5211